Home » Topics » Disease categories and therapies » Respiratory

Respiratory
RSS

Vertex reports phase III data on VX-659 triple combination regimen for cystic fibrosis

Nov. 28, 2018

Glenmark Pharmaceuticals discovers NADPH oxidase inhibitors

Nov. 28, 2018

Phase I results for PIN-201104 support progression to phase II for asthma

Nov. 27, 2018

Lung specificity means low tox for inhalable JAK inhibitor

Nov. 27, 2018

Theravance initiates phase I study of TD-8236 by inhalation for asthma

Nov. 26, 2018

Phase III study of VR-475 in severe uncontrolled asthma does not meet primary endpoint

Nov. 26, 2018

REALIST study explores use of mesenchymal stem cells to treat ARDS

Nov. 22, 2018

Phase I data on BLU-5937 support progression to phase II for chronic cough

Nov. 20, 2018

Phase III trial of STAGR-320 in house dust mite-induced allergic rhinitis meets primary endpoint

Nov. 20, 2018

Proteostasis Therapeutics patents mutant CFTR correctors

Nov. 19, 2018

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 28, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for July 28, 2026
New schizophrenia targets challenge trial design
BioWorld
The search for better schizophrenia therapies is moving beyond dopamine toward a growing number of experimental targets. According to researchers, the repeated...
Daybu readthrough in EU? Zevra’s NPC bid flounders
BioWorld
Zevra Therapeutics Inc. will try to follow in the footsteps of Acadia Pharmaceuticals Inc. with Rett syndrome drug Daybu (trofinetide) by asking the EMA’s...
Other news to note for July 27, 2026
BioWorld
Biopharma and med-tech happenings, including deals and partnerships, and other news in brief: Abbvie, Genmab, Merck, Par, Thyora.